Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.
Mbala-Kingebeni P, Pratt C, Mutafali-Ruffin M, Pauthner MG, Bile F, Nkuba-Ndaye A, Black A, Kinganda-Lusamaki E, Faye M, Aziza A, Diagne MM, Mukadi D, White B, Hadfield J, Gangavarapu K, Bisento N, Kazadi D, Nsunda B, Akonga M, Tshiani O, Misasi J, Ploquin A, Epaso V, Sana-Paka E, N'kasar YTT, Mambu F, Edidi F, Matondo M, Bula Bula J, Diallo B, Keita M, Belizaire MRD, Fall IS, Yam A, Mulangu S, Rimoin AW, Salfati E, Torkamani A, Suchard MA, Crozier I, Hensley L, Rambaut A, Faye O, Sall A, Sullivan NJ, Bedford T, Andersen KG, Wiley MR, Ahuka-Mundeke S, Muyembe Tamfum JJ. Mbala-Kingebeni P, et al. Among authors: mulangu s. N Engl J Med. 2021 Apr 1;384(13):1240-1247. doi: 10.1056/NEJMoa2024670. N Engl J Med. 2021. PMID: 33789012 Free PMC article.
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team. Ledgerwood JE, et al. Among authors: mulangu s. Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27. Vaccine. 2010. PMID: 21034824 Clinical Trial.
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ. Geisbert TW, et al. Among authors: mulangu s. J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16. J Virol. 2011. PMID: 21325402 Free PMC article.
Ebolavirus vaccines for humans and apes.
Fausther-Bovendo H, Mulangu S, Sullivan NJ. Fausther-Bovendo H, et al. Among authors: mulangu s. Curr Opin Virol. 2012 Jun;2(3):324-9. doi: 10.1016/j.coviro.2012.04.003. Epub 2012 May 4. Curr Opin Virol. 2012. PMID: 22560007 Free PMC article. Review.
Ebola virus outbreaks in Africa: past and present.
Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT. Muyembe-Tamfum JJ, et al. Among authors: mulangu s. Onderstepoort J Vet Res. 2012 Jun 20;79(2):451. doi: 10.4102/ojvr.v79i2.451. Onderstepoort J Vet Res. 2012. PMID: 23327370 Review.
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.
Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Sullivan NJ, Graham BS, Ledgerwood JE; VRC 206 Study Team. Sarwar UN, et al. Among authors: mulangu s. J Infect Dis. 2015 Feb 15;211(4):549-57. doi: 10.1093/infdis/jiu511. Epub 2014 Sep 14. J Infect Dis. 2015. PMID: 25225676 Free PMC article. Clinical Trial.
A new approach for monitoring ebolavirus in wild great apes.
Reed PE, Mulangu S, Cameron KN, Ondzie AU, Joly D, Bermejo M, Rouquet P, Fabozzi G, Bailey M, Shen Z, Keele BF, Hahn B, Karesh WB, Sullivan NJ. Reed PE, et al. Among authors: mulangu s. PLoS Negl Trop Dis. 2014 Sep 18;8(9):e3143. doi: 10.1371/journal.pntd.0003143. eCollection 2014 Sep. PLoS Negl Trop Dis. 2014. PMID: 25232832 Free PMC article.
Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Misasi J, et al. Among authors: mulangu s. Science. 2016 Mar 18;351(6279):1343-6. doi: 10.1126/science.aad6117. Epub 2016 Feb 25. Science. 2016. PMID: 26917592 Free PMC article.
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ. Corti D, et al. Among authors: mulangu s. Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224. Epub 2016 Feb 25. Science. 2016. PMID: 26917593
36 results